title: The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer.
abstract: Overexpression and/or hyperactivation of cyclin-dependent kinases (CDKs) are common features of most cancer types. CDKs have been shown to play important roles in tumor cell proliferation and growth by controlling cell cycle, transcription, and RNA splicing. CDK4/6 inhibitor palbociclib has been recently approved by the FDA for the treatment of breast cancer. CDK11 is a serine/threonine protein kinase in the CDK family and recent studies have shown that CDK11 also plays critical roles in cancer cell growth and proliferation. A variety of genetic and epigenetic events may cause universal overexpression of CDK11 in human cancers. Inhibition of CDK11 has been shown to lead to cancer cell death and apoptosis. Significant evidence has suggested that CDK11 may be a novel and promising therapeutic target for the treatment of cancers. This review will focus on the emerging roles of CDK11 in human cancers, and provide a proof-of-principle for continued efforts toward targeting CDK11 for effective cancer treatment.
authors.affiliation: Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.|Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA, United States of America.
authors.forename: Yubing
authors.initials: Y
authors.lastname: Zhou
authors.affiliation: Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA, United States of America.
authors.forename: Jacson K
authors.initials: JK
authors.lastname: Shen
authors.affiliation: Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA, United States of America.
authors.forename: Francis J
authors.initials: FJ
authors.lastname: Hornicek
authors.affiliation: Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
authors.forename: Quancheng
authors.initials: Q
authors.lastname: Kan
authors.affiliation: Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.|Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA, United States of America.
authors.forename: Zhenfeng
authors.initials: Z
authors.lastname: Duan
mesh_terms: D017209:Apoptosis; D001943:Breast Neoplasms / Q000378:metabolism; D002453:Cell Cycle; D049109:Cell Proliferation; D018844:Cyclin-Dependent Kinases / Q000378:metabolism*; D044127:Epigenesis, Genetic; D015972:Gene Expression Regulation, Neoplastic; D015316:Genetic Therapy; D006801:Humans; D008080:Liposarcoma / Q000378:metabolism; D009101:Multiple Myeloma / Q000378:metabolism; D009369:Neoplasms / Q000378:metabolism*; D012516:Osteosarcoma / Q000378:metabolism; D010766:Phosphorylation; D010879:Piperazines / Q000737:chemistry; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D011725:Pyridines / Q000737:chemistry; D012326:RNA Splicing; D016896:Treatment Outcome
chemical_list: D010879:Piperazines; D011725:Pyridines; D017346:Protein Serine-Threonine Kinases; C584437:CDK19 protein, human; D018844:Cyclin-Dependent Kinases; C500026:palbociclib
keywords: CDK11; CDKs inhibitor; cancer therapy; cell cycle; therapeutic target